The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.
A better understanding of inflammation and lung immunity over the past two decades has led to new, innovative treatments for ...
Correspondence to Dr Justin F Fraser, Neurological Surgery, University of Kentucky, Lexington, KY 40536, USA; Jfr235{at}uky.edu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback